FGFR2 and intrahepatic cholangiocarcinoma: This study employed an analytical framework similar to that utilized in our previous analysis of pemigatinib cost-effectiveness for patients with advanced ICC and FGFR2 fusions in comparison with mFOLFOX and 5-FU/LV treatments [30].